RESUMEN
A pilot study was performed over 91 days to determine if the activated sludge process could treat a segregated stripped sour water (SSW) stream from a petroleum refinery. The study was performed in two periods. The first period was terminated after 19 days, as a result of excessive sludge bulking. The elimination of sludge bulking during the 70-day second period is attributed to operational changes, which included aerating the influent to oxidize reduced sulfur, adjusting the influent pH, and adding micronutrients to satisfy biological requirements. The pilot plant provided a chemical oxygen demand (COD) removal of up to 93%. Nitrification was achieved, with effluent ammonia values < 1 mg-N/L. These results indicate that direct treatment of SSW with the activated sludge process is possible and has direct application to full-scale petroleum refinery wastewater plant upgrades.
Asunto(s)
Industria Química , Petróleo , Aguas del Alcantarillado , Contaminantes del Agua/aislamiento & purificaciónAsunto(s)
Cateterismo Venoso Central/métodos , Síndrome de la Vena Cava Superior , Catéteres de Permanencia/efectos adversos , Femenino , Humanos , Neoplasias del Mediastino/complicaciones , Persona de Mediana Edad , Neoplasias de Células Germinales y Embrionarias/complicaciones , Síndrome de la Vena Cava Superior/etiologíaAsunto(s)
Adenocarcinoma/terapia , Protocolos de Quimioterapia Combinada Antineoplásica , Neoplasias de la Mama/terapia , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/radioterapia , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/radioterapia , Ciclofosfamida/uso terapéutico , Femenino , Fluorouracilo/uso terapéutico , Humanos , Mastectomía , Metotrexato/uso terapéutico , Persona de Mediana Edad , Tamoxifeno/uso terapéuticoAsunto(s)
Carcinoma de Células Escamosas/terapia , Neoplasias Laríngeas/terapia , Anciano , Epiglotis , Humanos , MasculinoRESUMEN
Since 1975, all histologic subtypes of Stage III and IIIE nodular lymphoma patients were treated with a combination of radiotherapy and multiple-agent chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-Bleo). Fifty-eight patients were treated through 1979. Treatment consisted of two cycles of CHOP-Bleo alternating with sequential radiotherapy to clinically involved regions, and further CHOP-Bleo to a total of ten cycles. Radiotherapy doses ranged between 3000 and 4000 rad delivered in three to four weeks. Forty-six patients completed treatment. In the other 12 patients, treatment was interrupted because of progressive disease in seven, and myelosuppression in five. Overall five-year survival and disease-free survival results were 82% and 47%, respectively. Survival for those patients who completed therapy was 93%. By histopathology, survivals for all patients were: poorly differentiated lymphocytic, 100%; mixed cell, 80%; and histiocytic, 39%. Disease-free figures for all 58 patients were: poorly differentiated lymphocytic, 44%; mixed cell, 65%; and histiocytic, 35%. The extent of abdominal disease influenced five-year survival as follows: 100% for those who had only occult disease at staging laparotomy; 88% for those who were Stage III on the basis of a positive lymphangiogram; and 50% for those who had a palpable mass or required an exploratory laparotomy for symptoms. Five of seven patients with progression during protocol therapy have died. No patients died as a result of myelosuppression. A number of patients developed complications during treatment, none of which were fatal. Eight patients developed herpes zoster, four patients developed transient radiation hepatitis, and four patients had miscellaneous complications.
Asunto(s)
Antineoplásicos/administración & dosificación , Linfoma/terapia , Factores de Edad , Antineoplásicos/efectos adversos , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Laparotomía , Linfoma/patología , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Enfermedades Peritoneales/etiología , Radioterapia/efectos adversos , Dosificación Radioterapéutica , RecurrenciaRESUMEN
A case of BCG-induced granulomatous hepatitis, which developed 1 1/2 years after BCG immunotherapy for recurrent malignant melanoma, is described to document the development of this disease entity as a potential late complication of BCG immunotherapy. The clinical implications of the late development of BCG-induced granulomatous hepatitis, use of immunosuppressive chemotherapy, and possible alternatives for BCG in intratumor immunotherapy are discussed.